Moxicle – Patented Core Tablet Manufacturing Technology

Effective Moisture Blockage Increases Stability

Daewoong Pharmaceutical achieved a patent regarding the manufacture of core tablet antibiotics containing amoxicillin and clavulanate.

This “multiple film-coated Moxicle core tablet” patent is a ground breaking improvement in the stability issue of current core tablets containing amoxicillin and clavulanate; the technology effectively shuts off moisture from clavulanate, allowing stability over longer periods.

Daewoong Pharmaceutical plans to utilize this patented technology to expand its market over the globe, including Japan, Europe, and the United States. Currently it is applying for patents overseas in accordance with the Patent Cooperation Treaty (PTC) for international rights.

“Cored - tablets is an advanced technology that not only solves the stability issue, but also enables a dual release method of medicine (quick release of outer layer and slower release of the inner layer).” says Doctor Su-Jin Choi of the Daewoong Research Institute, pointing out “the superior technological capabilities of Daewoong Pharmaceutical will be shown through continued research and development in the future.”

Daewoong Pharmaceutical is currently utilizing the patented technology and began selling Moxicle (Cored) Tablets in March of 2004. Daewoong Pharmaceutical’s Moxicle is an antibiotic containing amoxicillin and clavulanate that shows excellent tissue penetration and strong broadband antibiotic effects without resistance, while leaving the immune system unharmed.